Substituted fused ring compound as well as pharmaceutical composition, preparation method and application thereof

CN119072478APending Publication Date: 2024-12-03SUZHOU YABAO PHARMA R&D CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380020672.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-28
Filing Date
2023-02-24
Publication Date
2024-12-03

Smart Images

  • Figure 00000044_0000
    Figure 00000044_0000
  • Figure 00000044_0001
    Figure 00000044_0001
Patent Text Reader

Abstract

The invention provides a substituted fused ring compound as shown in a formula (I) and a pharmaceutical composition, a preparation method and application thereof. The compound has a good LRRK2 kinase regulating / inhibiting effect, and can be used for treating diseases and diseases related to LRRK2 kinase activity and preparing drugs for the diseases and the diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Substituted fused ring compound and pharmaceutical composition, preparation method and use thereof

[0001] This application claims the priority benefit of two prior Chinese invention patent applications filed by the applicant with the State Intellectual Property Office of China on February 25, 2022, with application number 202210178818.7, entitled “Substituted fused ring compounds, pharmaceutical compositions thereof, preparation methods and uses thereof”; and with application number 202210470959.6, entitled “Substituted fused ring compounds, pharmaceutical compositions thereof, preparation methods and uses thereof”, filed with the State Intellectual Property Office of China on April 28, 2022. The entire texts of the above two prior patent applications are incorporated herein by reference. Field of the Invention

[0002] The present disclosure belongs to the field of LRRK2 kinase drugs, and specifically relates to substituted fused ring compounds and pharmaceutical compositions, preparation methods and uses thereof. Background Art

[0003] Parkinson's disease (PD) is a common neurodegenerative disease that affects 1-2% of the elderly population. Genome-wide association studies (GWAS) have linked 28 related genetic risk variants at 24 loci in non-familial PD. Among them, mutations in LRRK2 (Park8) have also been found in hereditary forms, identifying a common molecular pathway driving the pathogenesis of familial and non-familial PD and being the most common cause of related diseases (Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet, 2009, 41, 1308-1312.). The PD pathogenic LRRK2 mutation profile is primarily associated with the kinase (G2019S, I2020T) and ROC-COR domains (R1441C / G / H, Y1699C), meaning these enzyme activities are crucial for the disease. Pathogenic mutations are rare, accounting for about 2% of the overall population. However, in certain ethnic groups, the most common mutation, G2019S, is found in up to 40% of patients, activating the kinase by two to three times (West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. From The Cover: Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences, 2005, 102, 16842-16847.). In addition to pathogenic mutations, common genetic variations in LRRK2 are risk factors for sporadic PD (Tan, EK Identification of a common genetic risk variant (LRRK2Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore. 2006, 35, 840-842.).

[0004] In 2004, LRRK2 was identified as the gene responsible for the inheritance of PD, associated with the PARK8 locus, and found to consist of 51 exons, resulting in a large (268 kDa) protein. Subsequently, many LRRK2 primary structural variants were identified, including dominant mutations that segregate with familial PD and also occur in sporadic PD, as well as polymorphisms at the LRRK2 locus that increase the lifetime risk of developing sporadic PD.

[0005] LRRK2 is a multidomain protein with two enzymatic functions at its core. The GTPase domain contains the RAS (Ras of complex protein, ROC) of the complex protein, which terminates in a spacer domain at the C-terminus (COR) of the Roc domain, followed by a kinase domain belonging to a serine / threonine kinase. The enzymatic core is surrounded by protein-protein interaction domains, including Armadillo, ankyrin, and the N-terminal leucine-rich repeat (leucine-rich repeat, LRR) domain of LRRK2. The C-terminus of LRRK2 contains the WD40 domain, which is a region required for protein folding and can control the function and kinase activity of LRRK2 (Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, et al. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochemical Journal, 2012, 446, 99-111.). Interestingly, the recently described dominant pathogenic mutation occurs in the enzymatic core of LRRK2, suggesting that modifications in LRRK2 activity profoundly influence the development and progression of PD.

[0006] To date, nearly 40 single amino acid substitution mutations in LRRK2 have been associated with autosomal dominant PD. The most common LRRK2 mutation in Europe, which accounts for approximately 6% of familial PD and 3% of sporadic PD cases, involves the amino acid substitution of Gly2019 to a Ser residue. Gly2019 is located in the conserved DYG-Mg 2+The G2019S-LRRK2 mutation is expressed in a G2019S-LRRK2 binding motif, located in subdomain VII of the kinase domain. Recent reports indicate that this mutation enhances LRRK2 autophosphorylation and increases its ability to phosphorylate myelin basic protein by 2-3 fold. Cytotoxicity and inclusion body formation were observed when G2019S-LRRK2 was overexpressed in cell lines and primary neuronal cultures, both in the presence and absence of oxidative stress. These results, along with the fact that genetic inactivation of LRRK2 kinase activity demonstrated protective effects against this toxic phenotype, suggest that alterations in LRRK2 kinase activity may contribute to the neurotoxicity and pathogenesis of LRRK2-PD.

[0007] Studies have found that induced pluripotent stem cells (iPSCs) from patients with Parkinson's disease who harbor the LRRK2 G2019S mutation exhibit defects in neurite outgrowth and increased sensitivity to rotenone, which can be ameliorated by genetic correction of the G2019S mutation or by treating cells with small-molecule inhibitors of LRRK2 kinase activity (Reinhardt P, Schmid B, Burbulla Lena F, David C, Wagner L, et al. Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell, 2013, 12, 354-367.). Increased mitochondrial damage associated with the LRRK2 G2019S mutation in iSPCs was also blocked by genetic correction of the G2019S mutation.

[0008] Summary of the Invention

[0009] To improve the above technical problems, the present disclosure provides a compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound:

[0010] in:

[0011] W is selected from N or O;

[0012] R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-10 Alkyl, C3-10 Cycloalkyl, 3-10 membered heterocyclic group;

[0013] Every R a The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy;

[0014] Alternatively, two R a Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R c Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy;

[0015] R 2 Not present or selected from H or C 1-10 Alkyl; wherein, when W is selected from O, R 2 Not present; when W is selected from N, R 2 Selected from H or C 1-10 alkyl;

[0016] Alternatively, R 1 、R 2 Together with W, it forms an unsubstituted or optionally substituted group consisting of one, two or more R b substituted 3-10 membered heterocyclic group;

[0017] Every R b The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy;

[0018] Alternatively, two R b Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R c Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy;

[0019] Every Rc The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy;

[0020] X is selected from one, two or more R 3 substituted 5-10 membered heteroaryl;

[0021] Every R 3 The same or different, independently selected from unsubstituted or substituted by one, two or more R 4 Substituted with the following groups: C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl;

[0022] Alternatively, two R 3 Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R 4 Substituted with the following groups: C 3-10 Cycloalkyl, 3-10 membered heterocyclic group;

[0023] Every R 4 The same or different, independently selected from halogen, hydroxyl, cyano, unsubstituted or replaced by one, two or more R d Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, 5-10 membered heteroaryl; wherein, when R 4 Selected from C 1-6 When alkylene is 4 The carbon atom in R 3 The carbon atoms to which they are attached form a double bond;

[0024] Every R d The same or different, independently selected from halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy.

[0025] According to an embodiment of the present disclosure, R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-8Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group;

[0026] For example, R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclic group;

[0027] According to an embodiment of the present disclosure, each R a The same or different, independently selected from F, Cl, Br, C 1-6 alkyl;

[0028] As an example, R 1 Selected from -CH2CF3, -CH(CH3)CF3.

[0029] According to an embodiment of the present disclosure, R 1 、R 2 Together with W, it forms an unsubstituted or optionally substituted group consisting of one, two or more R b Substituted with the following groups:

[0030] According to an embodiment of the present disclosure, X is selected from one, two or more R 3 substituted 5-6 membered heteroaryl;

[0031] For example, X is selected from one, two or more R 3 Replaced

[0032] As an example, X is selected from

[0033] According to an embodiment of the present disclosure, R 3 Selected from unsubstituted or substituted by one, two or more R 4 Substituted with the following groups: C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl;

[0034] For example, R 3 Selected from unsubstituted or substituted by one, two or more R 4 Substituted groups: methyl, ethyl, propyl, isopropyl, cyclopropane, cyclobutane,

[0035] Every R 4 The same or different, independently selected from fluorine, chlorine, bromine, hydroxyl, cyano, unsubstituted or replaced by one, two or more Rd Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkylene, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group;

[0036] As an example, R 3 Selected from isopropyl,

[0037] According to a preferred embodiment of the present disclosure, the compound represented by formula (I) is preferably a compound represented by the following formula (II):

[0038] Among them, R 5 Selected from C substituted by one, two or more halogens 1-6 Alkyl, preferably C substituted by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 halogens 1-6 Alkyl, for example methyl or ethyl substituted by 1, 2, 3, 4 or 5 fluorine or chlorine atoms, for example trifluoromethyl;

[0039] R 6 Selected from C 1-6 an alkyl group, such as methyl, ethyl, propyl or isopropyl;

[0040] R 7 、R 8 、R 9 、R 10 The same or different, independently selected from H or C 1-6 Alkyl, such as H, methyl, ethyl, propyl or isopropyl;

[0041] R 11 、R 12 The same or different, independently selected from H or C 1-6 Alkyl, such as H, methyl, ethyl, propyl or isopropyl.

[0042] According to a preferred embodiment of the present disclosure, the compound represented by formula (I) is preferably a compound represented by the following formula (III):

[0043] Among them, R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 、R 12 Has the definition given above.

[0044] According to an exemplary embodiment of the present disclosure, the compound represented by formula (I) can be selected from the following compounds:

[0045] The present disclosure also provides a method for preparing the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled product, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, comprising the following reaction:

[0046] Among them, R 1 、R 2 , W and X have the definitions given above; P 1 is selected from amino protecting groups.

[0047] Preferably, the compound of formula (M2) is 1 The reaction is carried out under the conditions of , to obtain the compound shown in formula (I).

[0048] According to an embodiment of the preparation method disclosed herein, the P 1 is selected from amino protecting groups known to those skilled in the art. For example, suitable amino protecting groups can be selected from alkyloxycarbonyl (such as tert-butoxycarbonyl, etc.), cycloalkylalkoxycarbonyl (such as cyclohexylmethoxycarbonyl), substituted alkyloxycarbonyl (such as trichloroethoxycarbonyl, etc.), substituted arylalkyloxycarbonyl (such as p-nitrobenzyloxycarbonyl), arylalkyl (such as trityl or benzhydryl), heteroarylalkyl (such as pyridylalkyl, such as 2-pyridylmethyl, 4-pyridylmethyl), alkoxyarylalkyl (such as alkoxyphenylalkyl, such as p-methoxybenzyl, which can be abbreviated as "PMB").

[0049] According to an embodiment of the preparation method disclosed herein, a preparation method of a compound of formula (M2) is also provided, comprising the following reaction:

[0050] Among them, R 1 、R 2 , W, X, and P 1 has the meaning given above;

[0051] L 1 and L 2 The same or different, are independently selected from leaving groups capable of undergoing a coupling reaction.

[0052] According to an embodiment of the present disclosure, the preparation method of the compound of formula (M2) can be carried out by a coupling reaction known in the art, for example, by a Stille coupling reaction or a Suzuki coupling reaction.

[0053] As Stille coupling reaction or Suzuki coupling reaction known to those skilled in the art, L that meets the reaction requirements 1 and L 2 are known to those skilled in the art. For example, L 1 Can be selected from halogen, such as iodine; L 2 It may be selected from an alkyltin group or a borate group.

[0054] The present disclosure also provides a pharmaceutical composition comprising at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof.

[0055] The present disclosure also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof.

[0056] According to an embodiment of the present disclosure, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0057] According to an embodiment of the present disclosure, the pharmaceutical composition may further contain one or more additional therapeutic agents.

[0058] According to the embodiments of the present disclosure, the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof, or the pharmaceutical composition can be used to regulate the activity of LRRK kinase, especially LRRK2 kinase.

[0059] According to the embodiments of the present disclosure, the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope label, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, or the pharmaceutical composition can be used to prevent and / or treat diseases or conditions, which may include one, two or more selected from the following: neurodegenerative diseases, proliferative diseases, diseases related to protein kinases, lysosomal diseases, tau diseases and diseases caused by decreased dopamine levels, such as cancer, Parkinson's disease (PD) associated with GBA mutations, other α-synuclein diseases, tau diseases, Alzheimer's disease, Gaucher disease, Niemann disease type C (NPC), argyrophilic grain disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, hereditary frontotemporal dementia and Parkinson's disease associated with chromosome 17 (FTDP-17), withdrawal symptoms / relapse associated with drug addiction, etc.

[0060] The present disclosure also provides a method for regulating the activity of LRRK kinase, particularly LRRK2 kinase, comprising administering to a patient a preventively or therapeutically effective amount of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound thereof.

[0061] According to an embodiment of the present disclosure, the LRRK kinase is preferably LRRK2 kinase or a mutant or isoform thereof, or a combination thereof.

[0062] The present disclosure also provides a compound of formula (I), its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, or at least one of the pharmaceutical compositions for use in diseases or conditions associated with LRRK kinase, especially LRRK2 kinase activity.

[0063] According to an embodiment of the present disclosure, the LRRK kinase is preferably LRRK2 kinase or a mutant or isoform thereof, or a combination thereof.

[0064] The diseases or conditions associated with LRRK kinase, especially LRRK2 kinase activity, include one, two or more selected from the following: neurodegenerative diseases, proliferative diseases, diseases associated with protein kinase, lysosomal diseases, tau diseases and diseases caused by decreased dopamine levels, such as cancer, Parkinson's disease (PD) associated with GBA mutations, other α-synuclein diseases, tau diseases, Alzheimer's disease, Gaucher disease, Niemann disease type C (NPC), argyrophilic grain disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, hereditary frontotemporal dementia and Parkinson's disease associated with chromosome 17 (FTDP-17), withdrawal symptoms / relapse associated with drug addiction, etc.

[0065] The present disclosure also provides a method for preventing and / or treating a disease or condition, comprising administering to a patient at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope label, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound; wherein the disease or condition may include one, two or more selected from the following: neurodegenerative diseases, proliferative diseases, diseases associated with protein kinases, lysosomal diseases, tau diseases, and diseases caused by decreased dopamine levels, such as cancer, Parkinson's disease (PD) associated with GBA mutations, other α-synucleinopathies, tau diseases, Alzheimer's disease, Gaucher disease, Niemann disease type C (NPC), argyrophilic grain disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, hereditary frontotemporal dementia and Parkinson's disease associated with chromosome 17 (FTDP-17), withdrawal symptoms / relapse associated with drug addiction, etc.

[0066] In some embodiments, the patient suffering from the disease or condition is a human.

[0067] The present disclosure also provides a method for treating or preventing a disease or condition associated with LRRK kinase, particularly LRRK2 kinase activity, comprising administering to a patient at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope label, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound thereof.

[0068] The present disclosure also provides the use of at least one of the compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled product, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof in the preparation of a drug.

[0069] The medicament can be used for preventing and / or treating diseases or disorders associated with LRRK kinase, especially LRRK2 kinase activity.

[0070] Alternatively, the drug can be used to prevent and / or treat a disease or condition, wherein the disease or condition may include one, two or more selected from the following: neurodegenerative diseases, proliferative diseases, diseases associated with protein kinases, lysosomal diseases, tau diseases and diseases caused by decreased dopamine levels, such as cancer, Parkinson's disease (PD) associated with GBA mutations, other α-synuclein diseases, tau diseases, Alzheimer's disease, Gaucher disease, Niemann disease type C (NPC), argyrophilic grain disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, hereditary frontotemporal dementia and Parkinson's disease associated with chromosome 17 (FTDP-17), withdrawal symptoms / relapse associated with drug addiction, etc.

[0071] When used as a drug, the compounds of the present disclosure can be administered in the form of a pharmaceutical composition. These compositions can be prepared in a manner well known in the pharmaceutical field and can be administered by a variety of routes, depending on whether local or systemic treatment is required and the area to be treated. They can be administered topically (e.g., transdermal, skin, eye and mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, such as intrathecal or intraventricular administration. They can be administered parenterally in a single bolus form or can be administered by, for example, a continuous infusion pump. Topically administered pharmaceutical compositions and preparations may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, powder formulations and powders. Conventional pharmaceutical carriers, water, powder or oily bases, thickeners, etc. may be necessary or required.

[0072] In preparing the compositions of the present disclosure, the active ingredient is typically mixed with an excipient, diluted by the excipient, or enclosed in a carrier such as a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semisolid, or liquid substance that acts as a solvent, carrier, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (solid or dissolved in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0073] Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may also contain lubricants such as talc, sodium stearate, magnesium stearate, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl benzoate and hydroxypropyl benzoate; sweeteners and flavoring agents. The disclosed compositions can be formulated using methods known in the art to provide immediate release, sustained release or delayed release of the active ingredient after administration to the patient.

[0074] The pharmaceutical composition may be formulated in unit dosage form, each unit dosage form may contain about 1-1000 mg, for example about 5-1000 mg, more usually about 5-500 mg, such as 5-100 mg, 100-500 mg or 50-200 mg of active ingredient. As an example, each dose can contain 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg or 300 mg of active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as single dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[0075] The effective dosage of the active compound can range widely, and is generally administered in a pharmaceutically effective amount. However, it will be understood that the actual amount of compound administered is generally determined by the physician based on relevant circumstances, including the condition being treated, the route of administration chosen, the actual compound being administered; the age, weight, and response of the individual patient; the severity of the patient's symptoms, etc.

[0076] The therapeutic dosage of the disclosed compounds can be determined, for example, based on the specific therapeutic application, the method of administering the compound, the patient's health and condition, and the discretion of the prescribing physician. The proportion or concentration of the disclosed compounds in a pharmaceutical composition may not be fixed and depends on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the disclosed compounds, their racemates, stereoisomers, tautomers, isotopically labeled, N-oxides, hydrates, solvates, polymorphs, metabolites, pharmaceutically acceptable salts, pharmaceutically acceptable esters, or prodrugs thereof, can be provided in a physiologically buffered aqueous solution containing about 0.1 to 10% (w / v) of the compound for parenteral administration. Some typical dosage ranges are from about 1 μg / kg to about 1 g / kg of body weight per day. In certain embodiments, the dosage range is about 0.01 mg / kg to about 100 mg / kg body weight / day, for example, 0.1 mg / kg body weight / day, 0.2 mg / kg body weight / day, 0.3 mg / kg body weight / day, 0.4 mg / kg body weight / day, 0.5 mg / kg body weight / day, 0.6 mg / kg body weight / day, 0.7 mg / kg body weight / day, 0.8 mg / kg body weight / day, 0.9 mg / kg body weight / day, 1 mg / kg body weight / day, 5 mg / kg body weight / day, 10 mg / kg body weight / day, 15 mg / kg body weight / day, 20 mg / kg body weight / day, 25 mg / kg body weight / day, 30 mg / kg body weight / day, 35 mg / kg body weight / day, 40 mg / kg body weight / day, 45 mg / kg body weight / day, 50 mg / kg body weight / day. As an example, when the subject of administration is a human, the dosage given to the patient can be 57 mg / 70 kg to 171 mg / 70 kg. The dosage will likely depend on such variables as the type and extent of the disease or condition, the general health of the particular patient, the relative biological potency of the selected compound, the excipient formulation, and its route of administration. Effective dosages can be obtained by extrapolation from dose-response curves derived from in vitro or animal model test systems.

[0077] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition comprising a homogeneous mixture of a compound of the present disclosure. When these preformulation compositions are referred to as homogeneous, it is meant that the active ingredient is generally evenly distributed throughout the composition, such that the composition can be readily divided into equally effective unit dosage forms such as tablets, pills, and capsules. The solid preformulation is then divided into unit dosage forms of the type described above containing, for example, about 0.1 to 1000 mg of the active ingredient of the present disclosure. Each unit dosage form can contain about 1 to 1000 mg, for example, about 5 to 1000 mg, more typically about 5 to 500 mg, such as 5 to 100 mg, 100 to 500 mg, or 50 to 200 mg of the active ingredient. As an example, each dose can contain 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg or 300 mg of active ingredient.

[0078] The tablets or pills of the present disclosure may be coated or compounded to provide dosage forms that offer the advantage of prolonged action. For example, a tablet or pill may contain an inner dosage component and an outer dosage component, the outer dosage component being in the form of a film coating the outer dosage component. The two components may be separated by an enteric layer that serves to prevent disintegration in the stomach, thereby allowing the inner component to pass intact into the duodenum or to be released later. A variety of materials may be used for such enteric layers or coatings, including a variety of polymeric acids and mixtures of polymeric acids with such materials, such as shellac, cetyl alcohol, and cellulose acetate.

[0079] Liquid forms for oral or parenteral administration in which the disclosed compounds and compositions can be incorporated include aqueous solutions, appropriately flavored syrups, aqueous or oily suspensions; and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil; as well as elixirs and similar pharmaceutically acceptable vehicles.

[0080] Compositions for inhalation or insufflation include solutions, suspensions, and powders dissolved in pharmaceutically acceptable water or organic solvents, or mixtures thereof. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In certain embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. The compositions may be aerosolized using an inert gas. Aerosolized solutions may be inhaled directly from a nebulizing device, or the nebulizing device may be connected to a mask curtain or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered orally or nasally using a device that delivers the formulation in an appropriate manner.

[0081] The amount of a compound, its racemate, stereoisomer, tautomer, isotopically labeled, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug thereof, or pharmaceutical composition administered to a patient is not fixed and depends on the drug being administered, the purpose of administration, such as prophylaxis or treatment, the patient's condition, the route of administration, and the like. In therapeutic applications, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the disease being treated and the judgment of the attending clinician, which will depend on factors such as the severity of the disease, the patient's age, weight, and general condition. Some typical dosage ranges are from about 1 μg / kg to about 1 g / kg of body weight per day. In certain embodiments, the dosage range is about 0.01 mg / kg to about 100 mg / kg body weight / day, for example, 0.1 mg / kg body weight / day, 0.2 mg / kg body weight / day, 0.3 mg / kg body weight / day, 0.4 mg / kg body weight / day, 0.5 mg / kg body weight / day, 0.6 mg / kg body weight / day, 0.7 mg / kg body weight / day, 0.8 mg / kg body weight / day, 0.9 mg / kg body weight / day, 1 mg / kg body weight / day, 5 mg / kg body weight / day, 10 mg / kg body weight / day, 15 mg / kg body weight / day, 20 mg / kg body weight / day, 25 mg / kg body weight / day, 30 mg / kg body weight / day, 35 mg / kg body weight / day, 40 mg / kg body weight / day, 45 mg / kg body weight / day, 50 mg / kg body weight / day. As an example, when the subject of administration is a human, the dosage given to the patient can be 57 mg / 70 kg to 171 mg / 70 kg.

[0082] The compositions administered to patients can be in the form of pharmaceutical compositions as described above. These compositions can be sterilized by conventional sterilization techniques or by filtration. Aqueous solutions can be packaged for use as is or lyophilized, and the lyophilized formulation can be mixed with a sterile aqueous carrier prior to administration. The pH of the compound formulation is typically 3 to 11, more preferably 5 to 9, and most preferably 7 to 8. It will be appreciated that the use of some of the aforementioned excipients, carriers, or stabilizers may result in the formation of pharmaceutical salts.

[0083] The present disclosure provides the use of at least one of the compounds of formula (I), their racemates, stereoisomers, tautomers, isotopically labeled compounds, N-oxides, hydrates, solvates, polymorphs, metabolites, pharmaceutically acceptable salts, pharmaceutically acceptable esters, or prodrugs thereof in an analytical test for identifying compounds capable of inhibiting one or more kinases, preferably LRRK, more preferably LRRK2.

[0084] Preferably, the analytical test is a competitive binding activity assay.

[0085] More preferably, the competitive binding assay comprises contacting a compound according to the disclosure with a kinase and detecting any changes in the interaction between the compound according to the disclosure and the kinase.

[0086] Another aspect of the present disclosure provides a method for detecting binding of a compound of the present disclosure to a kinase, the method comprising the steps of:

[0087] (i) contacting at least one of the compounds of the present disclosure, its racemate, stereoisomer, tautomer, isotopically labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound with the kinase in the presence of the kinase and a known substrate;

[0088] (ii) detecting any changes in the interaction between said kinase and said known substrate. Beneficial effects

[0089] The compounds provided herein have good LRRK2 kinase regulation / inhibition effects and can be used to treat conditions and diseases associated with LRRK2 kinase activity, as well as to prepare medicaments for such conditions and diseases. The preparation method of the compounds disclosed herein is simple and has good application prospects.

[0090] Definitions and Explanations of Terms

[0091] Unless otherwise indicated, the definitions of groups and terms in this specification and claims, including definitions used as examples, exemplary definitions, preferred definitions, definitions in tables, and definitions of specific compounds in the Examples, may be arbitrarily combined and coupled with one another. The group definitions and compound structures resulting from such combinations and couplings should be understood to be within the scope of this specification and / or claims.

[0092] Unless otherwise indicated, the numerical ranges described in this specification and claims are equivalent to describing at least each specific integer value therein. For example, the numerical range "1-10" is equivalent to describing each integer value in the numerical range "1-10", namely 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. In addition, when certain numerical ranges are defined as "numbers", it should be understood that the two endpoints of the range, each integer within the range, and each decimal within the range are described. For example, "a number from 0 to 10" should be understood as describing not only each integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, but also at least the sum of each integer therein and 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9, respectively.

[0093] It should be understood that herein, when describing one, two or more, "more" should refer to an integer greater than 2, for example, greater than or equal to 3, such as 3, 4, 5, 6, 7, 8, 9 or 10.

[0094] The term "halogen" refers to fluorine, chlorine, bromine and iodine.

[0095] The term "C 1-40 "Alkyl" is understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1 to 40 carbon atoms. For example, "C 1-10 "Alkyl" means straight-chain and branched alkyl groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, "C 1-6 The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or the like or isomers thereof.

[0096] The term "C 3-10 "Cycloalkyl" is understood to mean a saturated monovalent monocyclic, bicyclic (eg bridged, spiro) hydrocarbon ring or tricyclic alkane having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. 3-10The cycloalkyl group may be a monocyclic hydrocarbon group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or a bicyclic hydrocarbon group such as borneol, indolyl, hexahydroindolyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, 2,7-diazaspiro[3,5]nonyl, 2,6-diazaspiro[3,4]octyl, or a tricyclic hydrocarbon group such as adamantyl.

[0097] Unless otherwise defined, the term "3-10 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic ring or ring system, for example, a 4-, 5-, 6- or 7-membered monocyclic ring, a 7-, 8-, 9- or 10-membered bicyclic ring (such as a fused ring, a bridged ring, a spirocyclic ring) or a 10-membered tricyclic ring system, and contains at least one, for example 1, 2, 3, 4, 5 or more heteroatoms selected from O, S and N, wherein N and S may also be optionally oxidized to various oxidation states to form nitrogen oxides, -S(O)- or -S(O)2- states. Preferably, the heterocyclyl may be selected from "3-10 membered heterocyclyl". The heterocyclyl may be connected to the rest of the molecule via any one of the carbon atoms or a nitrogen atom (if present). The heterocyclyl may include fused or bridged rings and spirocyclic rings. In particular, the heterocyclic group may include, but is not limited to, a 4-membered ring such as azetidinyl, oxetanyl; a 5-membered ring such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or a 7-membered ring such as diazepanyl. Optionally, the heterocyclic group may be benzo-fused. The heterocyclic group may be bicyclic, for example, but not limited to, a 5,5-membered ring such as hexahydrocyclopenta [c] pyrrole-2 (1H) -yl ring, or a 5,6-membered bicyclic ring such as hexahydropyrrolo [1,2-a] pyrazine-2 (1H) -yl ring. The heterocyclic group may be partially unsaturated, i.e., it may contain one or more double bonds, such as, but not limited to, dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl, or it may be benzo-fused, such as, but not limited to, dihydroisoquinolinyl. When the 3-10 membered heterocyclic group is linked to other groups to form the compounds of the present disclosure, the linking may be to a carbon atom of the 3-10 membered heterocyclic group or to a heterocyclic atom on the 3-10 membered heterocyclic group ring. For example, when the 3-10 membered heterocyclic group is selected from piperazinyl, the linking may be to a nitrogen atom on the piperazinyl ring and to a carbon atom at the para position thereof. Alternatively, when the 3-10 membered heterocyclic group is selected from piperidinyl, the linking may be to a nitrogen atom on the piperidinyl ring and to a carbon atom at the para position thereof.

[0098] The term "C 6-10 The term "aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic or bicyclic (e.g. fused, bridged, spiro) hydrocarbon ring having 6 to 10 carbon atoms, which may be a single aromatic ring or a polyaromatic ring fused together, in particular a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or biphenyl, or a ring having 9 carbon atoms ("C9 aryl"), such as indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 Aryl "), such as naphthyl. When the C6-10 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the position of substitution, and for example, substitution may be at the ortho, para or meta position.

[0099] The term "5-10 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic (e.g., fused, bridged, spiro) or tricyclic aromatic ring systems having 5 to 10 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, preferably 1 to 3 heteroatoms each independently selected from N, O and S and, in each case, which may be benzofused. "Heteroaryl" also refers to a group in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclyl rings, wherein the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3- , 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aHcarbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbazolylcarbazolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-piperidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenanthrolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-benzoisoquinolinyl , 2-, 3-, 4- or thieno[2,3-b]furyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10- or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6- or 7-2H-furo[3,2-b]pyranyl, 2-, 3-, 4-, 5-, 7- or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3- or 5-1H-pyrazolo[4,3-d]-oxazolyl, 2-, 4- or 54H-imidazo[4,5-d]thiazolyl, 3-, 5- or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5- or 6-imidazo[2,1-b]thiazolyl, 1-, 3-, 6-, 7-, 8- or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10 or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6- or 7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thiophenyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroaryl groups include, but are not limited to, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-, or 7-benzothiazolyl. When the 5- to 10-membered heteroaryl group is linked to other groups to form the compounds of the present disclosure, the linking may be to a carbon atom of the 5- to 10-membered heteroaryl ring or to a heteroatom of the 5- to 10-membered heteroaryl ring. When the 5- to 10-membered heteroaryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the substitution site, for example, a hydrogen atom connected to a carbon atom on a heteroaryl ring may be substituted, or a hydrogen atom connected to a heteroatom on a heteroaryl ring may be substituted.

[0100] The term "spirocyclic" refers to a ring system in which two rings share one ring atom.

[0101] The term "fused ring" refers to a ring system in which two rings share two ring atoms.

[0102] The term "bridged ring" refers to a ring system in which two rings share three or more ring atoms.

[0103] Unless otherwise specified, a heterocyclic group, heteroaryl group, or heteroarylene group includes all possible isomeric forms thereof, such as positional isomers thereof. Thus, for some illustrative non-limiting examples, the following may be substituted or bonded to other groups at one, two, or more positions of the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-position, etc. (if present): pyridin-2-yl, pyridin-2-ylene, pyridin-3-yl, pyridin-3-ylene, pyridin-4-ylene, and pyridin-4-ylene; thienyl or thienylene group includes thien-2-yl, thien-2-ylene, thien-3-ylene, and thien-3-ylene; pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, and pyrazol-5-yl.

[0104] The term "oxo" refers to a substituent in which a carbon atom, a nitrogen atom, or a sulfur atom is oxidized to form an oxy group (=O).

[0105] Unless otherwise stated, the definitions of terms herein also apply to groups containing the term, e.g. 1-10 The definition of alkyl also applies to C 1-10 Alkyloxy, C 3-10 Cycloalkyloxy, etc.

[0106] It will be appreciated by those skilled in the art that the compounds of formula (I) may exist in the form of various pharmaceutically acceptable salts. If these compounds have a basic center, they may form acid addition salts; if these compounds have an acidic center, they may form base addition salts; if these compounds contain both an acidic center (e.g., a carboxyl group) and a basic center (e.g., an amino group), they may also form internal salts.

[0107] The compounds of the present disclosure may exist in the form of solvates (e.g., hydrates), wherein the compounds of the present disclosure contain a polar solvent, such as water, methanol, or ethanol, as a structural element of the crystal lattice of the compound. The amount of the polar solvent, particularly water, may be present in a stoichiometric or non-stoichiometric ratio.

[0108] Depending on their molecular structure, the compounds of the present invention may be chiral and therefore may exist in various enantiomeric forms. Thus, these compounds may exist in racemic or optically active forms. The compounds of the present invention encompass isomers or mixtures thereof, racemates, in which each chiral carbon is in the R or S configuration. The compounds of the present invention or their intermediates can be separated into enantiomeric compounds by chemical or physical methods well known to those skilled in the art, or used in this form for synthesis. In the case of racemic amines, diastereomers are prepared from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g., N-benzoylproline or N-phenylsulfonylproline) or various optically active camphorsulfonic acids. Chromatographic enantiomer resolution can also be advantageously performed with the aid of optically active resolving agents (e.g., dinitrobenzoylphenylglycine, cellulose triacetate or other carbohydrate derivatives or chirally derivatized methacrylate polymers immobilized on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, e.g., hexane / isopropanol / acetonitrile.

[0109] The corresponding stable isomers can be separated according to known methods, for example by extraction, filtration or column chromatography.

[0110] The term "patient" refers to any animal including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses or primates, and most preferably humans.

[0111] The term "therapeutically effective amount" refers to the amount of an active compound or drug that will elicit the biological or medical response that a researcher, veterinarian, physician, or other clinician is seeking in a tissue, system, animal, individual, or human, and includes one or more of the following: (1) Preventing disease: e.g., preventing a disease, disorder, or condition in an individual who is susceptible to the disease, disorder, or condition but has not yet experienced or developed the pathology or symptoms of the disease. (2) Inhibiting disease: e.g., inhibiting the disease, disorder, or condition (i.e., preventing further development of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition. (3) Alleviating disease: e.g., alleviating the disease, disorder, or condition (i.e., reversing the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition. The therapeutically effective amount can be initially estimated from cell culture assays, and initial doses can also be estimated from in vivo data. Using these preliminary guidelines, one of ordinary skill in the art can determine the effective dose in humans. In addition, the toxicity and therapeutic efficacy of the compounds described herein can also be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD 50 and ED 50 .

[0112] The term "disease or condition associated with LRRK kinase or LRRK2 kinase activity" refers to a disease or condition characterized by inappropriate activity of the kinase or excessive activity of the kinase as defined herein. Inappropriate activity refers to (i) expression of the kinase in cells that do not normally express the kinase; (ii) increased expression of the kinase, resulting in undesirable cell proliferation, differentiation and / or growth; or (iii) decreased expression of the kinase, resulting in an undesirable reduction in cell proliferation, differentiation and / or growth. Excessive activity of a kinase refers to the amplification of a gene encoding a particular kinase or the generation of a certain level of kinase activity, which can be associated with a cell proliferation, differentiation and / or growth disorder (i.e., as the level of the kinase increases, the severity of one or more symptoms of the cellular disorder increases). Excessive activity can also be the result of ligand-independent or constitutive activation due to a mutation, such as a deletion of a fragment of the kinase responsible for ligand binding.

[0113] Examples of "excipients" described in the present disclosure are described in "Handbook of Pharmaceutical Excipients, 2nd edition, 1994, edited by A Wade and PJ Weller".

[0114]

[00146] "Carriers" or "diluents" as used in this disclosure are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro, ed. 1985).

[0115] The choice of pharmaceutical carrier, adjuvant or diluent can be selected according to the expected route of administration and standard pharmaceutical practice. The pharmaceutical composition may contain or additionally contain any suitable adhesive, lubricant, suspending agent, coating agent, solubilizer, buffer, flavoring, surfactant, thickening agent, preservative (including antioxidant) etc. as a carrier, adjuvant or diluent, as well as the substance contained in order to make the preparation isotonic with the blood of the recipient.

[0116] Pharmaceutical formulations suitable for oral administration in which the carrier is a solid are most preferably in the form of unit dose formulations, such as pills, capsules, or tablets, each containing a predetermined amount of the active compound. Tablets can be prepared by compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing the active compound in a free-flowing form (such as a powder or granules) in a suitable machine, optionally mixed with a binder, lubricant, inert diluent, lubricating substance, surfactant, or dispersant. Molded tablets can be prepared by molding the active compound and an inert liquid diluent. The tablets can optionally be coated, or, if not coated, can optionally be printed with a symbol. Capsules can be prepared by filling the active compound, alone or in admixture with one or more auxiliary ingredients, into a capsule shell and then sealing it in a conventional manner. Cachets are similar to capsules, in which the active compound, along with any auxiliary ingredients, is sealed in rice paper film. The active compound can also be formulated as dispersible granules, which can, for example, be suspended in water or sprinkled on food before administration. The granules can be packaged, for example, in sachets. Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water liquid emulsion.

[0117] The term "pharmaceutically acceptable salt" includes suitable acid addition salts or base salts thereof. For suitable pharmaceutical salts, see J Pharm Sci, 66, 199, 1977, Berge et al. Salts are formed, for example, with strong inorganic acids, such as mineral acids, for example hydrohalic acids (e.g. hydrochloric acid, hydrobromic acid and hydroiodic acid), sulfuric acid, phosphosulfates, hydrogensulfates, hemisulfates, thiocyanates, persulfates and sulfonic acids; with strong organic carboxylic acids, such as unsubstituted or substituted (e.g. by halogen) alkanecarboxylic acids having 1 to 4 carbon atoms, such as acetic acid; with saturated or unsaturated dicarboxylic acids, for example oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or tetraphthalic acid; with hydroxycarboxylic acids, for example ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; with amino acids, for example aspartic acid or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as unsubstituted or substituted (e.g. by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids, such as methane- or p-toluenesulfonic acid.

[0118] Preferred salts include, for example, acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanoate, glucoheptonate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmitate, pectinate, 3-phenylpropionate, picrate, pivalate, propionate, tartrate, lactobionate, pivolate, camphorate, undecanoate and succinate, organic sulfonic acids such as methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, camphorsulfonate, 2-naphthalenesulfonate, benzenesulfonate, p-chlorobenzenesulfonate and p-toluenesulfonate; and inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, hydrogensulfate, hemisulfuric acid, thiocyanic acid, persulfuric acid, phosphoric acid and sulfonic acid.

[0119] The term "pharmaceutically acceptable ester" refers to the use of organic acids or alcohols / hydroxides to form esters with functional groups in the structure of the disclosed compounds that can be esterified. Organic acids include carboxylic acids, such as unsubstituted or substituted (e.g., by halogen) alkanecarboxylic acids of 1 to 12 carbon atoms, such as acetic acid; saturated or unsaturated dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or tetraphthalic acid; hydroxycarboxylic acids, such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; amino acids, such as aspartic acid or glutamic acid; benzoic acid; or organic sulfonic acids, such as unsubstituted or substituted (e.g., by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids, such as methane- or p-toluenesulfonic acid. Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide. Alcohols include alkanols of 1 to 12 carbon atoms which may be unsubstituted or substituted (eg, by halogens).

[0120] The term "isotopically labeled" means that at least one atom in the disclosed compound is replaced by an isotope. Examples of such isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as the corresponding 2 H. 3 H. 13 C. 14 C. 15 N. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Using isotopes such as deuterium (i.e. 2H) substitution may provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in certain circumstances. For example, the present disclosure includes compounds of formula (I) in which any hydrogen atom is replaced by a deuterium atom.

[0121] The term "prodrug compound" refers to a covalently bonded compound that releases the active parent drug according to formula (I) in vivo. Such prodrugs are generally compounds of the present disclosure in which one or more appropriate groups have been modified so that the modification can be reversed after administration to a human or mammalian subject. Reversal is usually performed by enzymes naturally occurring in such subjects, although a second agent may be administered with the prodrug for reversal in vivo. Examples of such modifications include the pharmaceutically acceptable esters described above, wherein such reversal can be performed by esterases, etc.

[0122] The term "polymorph" refers to various crystalline forms, polymorphic forms, and hydrated forms of the disclosed compounds. It is well established in the pharmaceutical industry that chemical compounds can be isolated in any of these forms by methods of purification and / or separation of solvents used in the synthetic preparation of such compounds.

[0123] The term "administration" means that the pharmaceutical composition of the present disclosure is applicable to rectal, intranasal, intrabronchial, topical (including oral and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intraarterial and intradermal), intraperitoneal or intrathecal administration. Preferably, the preparation is a preparation for oral administration. The preparation can be conveniently presented in the form of a unit dosage form, that is, in the form of discrete portions comprising a unit dose or a plurality of units or subunits of a unit dose. As an example, the preparation can be in the form of tablets and sustained-release capsules and can be prepared by any method well known in the pharmaceutical field.

[0124] The formulations of the present disclosure for oral administration can be presented as discrete units such as capsules, gels, drops, cachets, pills or tablets, each containing a predetermined amount of the active agent; as a powder or granules; as a solution, emulsion or suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; or as a bolus formulation, etc. Preferably, each dose of these compositions contains 1 to 250 mg and more preferably 10-100 mg of the active ingredient.

[0125] For compositions for oral administration (e.g., tablets and capsules), solvents and / or common excipients are also included, such as binders, such as syrup, gum arabic, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, sucrose, and starch; fillers and carriers, such as corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid; and lubricants, such as magnesium stearate, sodium stearate, and other metal stearates, glycerol stearate, stearic acid, silicone fluid, talcum wax, oil, and colloidal silicon dioxide. Flavoring agents such as peppermint, wintergreen oil, cherry flavor, etc. may also be used. It may be necessary to add a colorant to make the dosage form easily recognizable. Tablets may also be coated by methods well known in the art.

[0126] Other formulations suitable for oral administration include lozenges containing the active agent in a flavored basis, usually sucrose and acacia or tragacanth; pastilles containing the active agent in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes containing the active agent in a suitable liquid carrier.

[0127] Other administration forms include solutions or emulsions for intravenous, intraarterial, intrathecal, subcutaneous, intradermal, intraperitoneal or intramuscular injection and prepared from sterile or sterilizable solutions. Injectable forms usually contain between 10-1000 mg, preferably between 10-250 mg, of active ingredient per dose.

[0128] The administration may also be in the form of combined administration, i.e., one or more compounds of the present disclosure may be administered in combination with one or more other active agents. In this case, the compounds of the present disclosure and one or more other active agents may be administered continuously, simultaneously or sequentially.

[0129] Analytical Test

[0130] Another aspect of the present disclosure relates to the use of a compound as described above in an assay for identifying additional candidate compounds capable of inhibiting one or more kinases, more preferably LRRK, even more preferably LRRK2.

[0131] Preferably, the assay is a competitive binding assay.

[0132] More preferably, the competitive binding assay comprises contacting a compound of the disclosure with a kinase, preferably LRRK, more preferably LRRK2, and a candidate compound, and detecting any changes in the interaction between the compound of the disclosure and the kinase.

[0133] Preferably, candidate compounds are generated by SAR modification of the disclosed compounds.

[0134] As used herein, the term "SAR modification" refers to the standard method of altering a given compound by chemical derivatization.

[0135] Therefore, in one aspect, the identified compound can be used as a model (e.g., template) for developing other compounds. The compound used in this test can be free in solution, fixed on a solid support, carried on a cell surface, or located within a cell. The activity elimination or formation of a binding complex between the compound and the agent to be tested can be measured.

[0136] The analytical tests of the present disclosure can be screening, whereby a large number of agents are tested. In one aspect, the analytical assays of the present disclosure are high throughput screening.

[0137] The present disclosure also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding to a compound specifically compete with a test compound for binding to the compound.

[0138] Another technique for screening is provided for high throughput screening (HTS) of agents having suitable binding affinity for a substance and is based on the method described in detail in WO 84 / 03564.

[0139] It is expected that the analytical assay methods of the present disclosure will be suitable for both small-scale and large-scale screening of test compounds as well as for quantitative assays.

[0140] Preferably, a competitive binding assay comprises contacting a disclosed compound with a kinase in the presence of a known substrate for the kinase and detecting any change in the interaction between the kinase and the known substrate.

[0141] Another aspect of the present disclosure provides a method for detecting binding of a ligand to a kinase, the method comprising the steps of:

[0142] (i) contacting a ligand with the kinase in the presence of a known substrate of the kinase;

[0143] (ii) detecting any change in the interaction between the kinase and the known substrate;

[0144] and wherein the ligand is a compound of the disclosure.

[0145] One aspect of the present disclosure relates to a method comprising the steps of:

[0146] (a) performing the above-mentioned determination method;

[0147] (b) identifying one or more ligands capable of binding to the ligand binding domain;

[0148] (c) modifying the one or more ligands capable of binding to the ligand binding domain;

[0149] (d) performing the above-mentioned determination method;

[0150] (e) optionally preparing a pharmaceutical composition comprising the one or more ligands.

[0151] The present disclosure also relates to ligands identified by the above methods.

[0152] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a ligand identified by the above method.

[0153] Another aspect of the present disclosure relates to the use of a ligand identified by the above method in the preparation of a pharmaceutical composition for treating one or more disorders.

[0154] The above methods can be used to screen for ligands that are useful as inhibitors of one or more kinases. BRIEF DESCRIPTION OF THE DRAWINGS

[0155] FIG1 is an example of a western blot result showing the expression level of LRRK2 in brain tissue of LRRK2-G2019S mice in Example 12;

[0156] Figure 2 shows the effect of compound 527 in Example 12 on the phosphorylation level of LRRK2 in the brain tissue of LRRK2-G2019S mice, wherein: data are mean ± sample standard deviation (mean ± SE), n = 8; * represents p < 0.05 relative to the vehicle control group, *** represents p < 0.001 relative to the vehicle control group, and one-way analysis of variance was used. DETAILED DESCRIPTION

[0157] The technical solutions of the present disclosure will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present disclosure and should not be construed as limiting the scope of protection of the present disclosure. All technologies implemented based on the above content of the present disclosure are included within the scope of protection intended by the present disclosure.

[0158] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0159] The abbreviations in the context of the present disclosure have the following meanings: DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCM dichloromethane DEA diethylamine DIEA diisopropylethylamine DMA N,N-dimethylacetamide DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EA, EtOAc ethyl acetate IPA isopropanol MTBE tert-butyl methyl ether NIS N-iodosuccinimide NMR nuclear magnetic resonance PE petroleum ether PMBCl p-methoxybenzyl chloride RT, t R Retention time SFC supercritical fluid chromatography Tf trifluoromethanesulfonyl TfOH trifluoromethanesulfonic acid TFA trifluoroacetic acid THF tetrahydrofuran UV ultraviolet light

[0160] Chromatography

[0161] High pressure liquid chromatography (HPLC) was used with monitoring by a multi-wavelength UV detector. Typical mobile phases used for the separations were PE / EA, DCM / MeOH, or water / MeCN.

[0162] Analytical methods

[0163] The spectrometer was used to analyze the chromatograms in the solvents at room temperature using a Bruker AV 400 spectrometer. 1 H nuclear magnetic resonance (NMR) spectra, unless otherwise indicated. In all cases, NMR data are consistent with the proposed structure. The characteristic chemical shift (δ) is given in parts per million using conventional abbreviations for designating major peaks: for example, s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; br, broad. Mass spectra were recorded using an Agilent 1290 Infinity / 6460 triple Quad LCMS. When thin layer chromatography (TLC) was used, it refers to silica gel TLC.

[0164] Compound preparation

[0165] Where the preparation of starting materials is not described, these are either commercially available, known in the literature, or readily available to one skilled in the art using standard procedures. Where compounds are described as being prepared analogously to the previous examples or intermediates, it will be understood by one skilled in the art that reaction times, equivalents of reagents, and temperatures may be varied for each particular reaction, and that different workup or purification techniques may be necessary or desirable.

[0166] Example 1: Preparation of Compound 390

[0167] Step 1: Synthesis of (2S,6R)-4-(6-chloropyrimidin-4-yl)-2,6-dimethylmorpholine (1-1)

[0168] At room temperature, DIEA (87.7 g, 0.680 mol) and (2R, 6S)-2,6-dimethylmorpholine (40.5 g, 0.350 mol) were added to a solution of 4,6-dichloropyrimidine (50.0 g, 0.340 mol) in IPA (1000 mL). The mixture was stirred at room temperature for 1 hour. Concentrated to remove the solvent, and the residue was diluted in EtOAc (500 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE / EA=1:1) to give (2S, 6R)-4-(6-chloropyrimidin-4-yl)-2,6-dimethylmorpholine (1-1, 76.0 g, 98.4%) as a white solid. m / z(ESI) + :228.0[M+H] + .

[0169] Step 2: Synthesis of (2S,6R)-2,6-dimethyl-4-(6-(trimethyltinyl)pyrimidin-4-yl)morpholine (1-2)

[0170] Under N2 atmosphere, a dry three-necked flask containing xylene (100 mL) was heated to 150 ° C, and a solution of compound 1-1 (10.0 g, 44.1 mmol) in xylene (50 mL), 1,1,1,2,2,2-hexamethylstilbene (18.8 g, 57.3 mmol), Pd (PPh3) 2Cl2 (3.00 g, 4.40 mmol) and PPh3 (2.30 g, 8.80 mmol) were added dropwise. The resulting mixture was stirred at 150 ° C for 2 hours. The reaction mixture was cooled to room temperature and diluted with PE, and then filtered through celite. The filtrate was concentrated in vacuo to give a crude product (1-2, 16.0 g, purity about 60%) as a yellow solid, which was used in the next step without further purification. m / z (ESI) +:358.1[M+H] + .

[0171] Step 3: Synthesis of 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine (1-3)

[0172] To a solution of 4-chloro-1H-pyrazolo[4,3-c]pyridine (50.0 g, 0.326 mol) in DMF (500 mL) was added NIS (88.0 g, 0.390 mol) at room temperature. After the addition was complete, the mixture was heated to 80°C and stirred for 2 hours. The mixture was then concentrated to give a residue, which was treated with saturated aqueous NaHSO3 solution (500 mL) and stirred for 30 minutes. The solid formed was collected by filtration, washed with water (2 L), and then dried in vacuo to give the product (1-3, 83.0 g, 91.2%) as a brown solid. m / z (ESI) + :279.8[M+H] + .

[0173] Step 4: Synthesis of 4-chloro-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridine (1-4)

[0174] Under an ice-water bath, PMBCl (49.6 g, 0.320 mol) and NaOH (23.2 g, 0.580 mol) were added to a DMF (800 mL) solution of compound 1-3 (80.0 g, 0.290 mol). The mixture was stirred at room temperature for 20 hours, concentrated to remove the solvent, and the residue was dissolved in EtOAc (500 mL), washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to obtain a residue, which was slurried with PE and EA (PE / EA=1:1) and stirred overnight. Filter and dry the solid to obtain compound 1-4 (104 g, 89.7%) as an off-white solid. m / z (ESI) + :399.7[M+H] + .

[0175] Step 5: Synthesis of N-cyclopropyl-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (1-5)

[0176] A mixture of compound 1-4 (7.00 g, 17.5 mmol) and cyclopropaneamine (10.0 g, 175 mmol) in DIEA (50 ml) was heated to 140° C. and stirred for 2 days. The mixture was concentrated in vacuo to remove the solvent and then diluted in EA and brine. The separated organic layer was dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (100% EA) to obtain compound 1-5 (5.00 g, 68.0%) as a brown solid. m / z (ESI) + :421.1[M+H] + .

[0177] Step 6: Synthesis of N-cyclopropyl-3-(6-((2S,6R)-2,6-dimethylmorpholinyl)pyrimidin-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (1-6)

[0178] Under N2 atmosphere, to a mixture of compound 1-5 (200 mg, 0.476 mmol) and crude compound 1-2 (purity about 60%, 425 mg, 0.714 mmol) in DMF (10 mL), Pd(PPh3)2Cl2 (34 mg, 0.048 mmol), PPh3 (25 mg, 0.095 mmol) and CuI (9 mg, 0.043 mmol) were added. The mixture was degassed and purged with nitrogen 3 times, then stirred at 120 ° C for 1 hour. Cooled to room temperature and diluted in EA, the organic matter was washed with saturated KF aqueous solution and brine, the organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=19:1) to obtain compound 1-6 (50.0 mg, 21.6%) as a light brown solid. m / z (ESI) + :486.1[M+H] + .

[0179] Step 7: Synthesis of N-(3,3-difluorocyclobutyl)-3-(6-(2S,6R)-2,6-dimethylmorpholinyl)pyrimidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (390)

[0180] To a TFA (5 mL) solution of compound 1-6 (50.0 mg, 0.103 mmol) was added TfOH (0.5 mL). The resulting mixture was stirred at room temperature for 1 hour. Concentrated to remove the solvent and diluted in DCM. The organic layer was then washed with a 1M NaOH aqueous solution and brine, separated, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by preparative TLC (DCM / MeOH=10:1) to obtain compound 390 (6 mg) as a pale white solid. 1 HNMR(400MHz,CD3OD)δ8.68(d,J=1.0Hz,1H),7.72-7.65(m,2H),7.10(d,J=7.2Hz,1H),4.26-4.72(m,2H),3.76-3.64 (m,2H),2.94-2.86(m,1H),2.78-2.65(m,2H),1.28(d,J=6.2Hz,6H),1.20-1.13(m,2H),0.95-0.88(m,2H).m / z(ESI) + :366.0[M+H] + .

[0181] Referring to Example 1, the corresponding starting materials were used in step 5 to prepare the compounds shown in Table 1.

[0182] Table 1

[0183] Example 2: Preparation of Compound 397

[0184] Step 1: Synthesis of (cis)-2,6-dimethyltetrahydro-2H-pyran-4-ol (2-1)

[0185] Pd / C (10%, 0.500 g) was added to a solution of 2,6-dimethyl-4H-pyran-4-one (5.00 g, 40.3 mmol) in ethanol (50 mL), and the reaction mixture was stirred at 35°C under H2 (4 atm) for 20 h. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure to give compound 2-1 (5.00 g, 95.4%) as light yellow crystals. m / z (ESI) + :131.1[M+H] + .

[0186] Step 2: Synthesis of 1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde-2-yl)-1H-pyrazole (2-2)

[0187] To a suspension of 4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-1H pyrazole (5.00 g, 25.8 mmol) and Cs2CO3 (12.6 g, 38.6 mmol) in acetonitrile (100 mL) was added 2-iodopropane (6.57 g, 38.6 mmol) at room temperature. The mixture was heated to 60 ° C and stirred for 20 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA=4:1) to give compound 2-2 (5.80 g, 95.2%) as a colorless oil. 1 HNMR (300MHz, CDCl3) δ7.78 (s, 1H), 7.73 (s, 1H), 4.51 (hept, J = 6.7Hz, 1H), 1.49 (d, J = 6.7Hz, 6H), 1.31 (s, 12H).

[0188] Step 3: Synthesis of 4-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)oxy)-3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridine (2-3):

[0189] At room temperature, NaH (60%) (187 mg, 4.68 mmol) was added to a solution of compound 2-1 (510 mg, 3.90 mmol) in DMA (10 mL). After stirring for 10 minutes, compound 1-4 (1.57 g, 3.9 mmol) was added. The resulting mixture was heated to 120 ° C and stirred for 20 hours. After cooling to room temperature, water (100 mL) was added and the resulting mixture was extracted with EtOAc (100 mL * 2). The combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA = 3: 2) to obtain compound 2-3 (680 mg, 35.3%) as a light yellow oil. m / z (ESI) + :493.7[M+H] + .

[0190] Step 4: Synthesis of 4-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)oxy)-3-(1-isopropyl-1H-pyrazol-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridine (2-4):

[0191] To a mixture of compound 2-3 (176 mg, 0.357 mmol), compound 2-2 (90 mg, 0.38 mmol) and Na2CO3 (121 mg, 1.14 mmol) in DMSO / H2O (5 mL / 0.5 mL) was added Pd(dppf)Cl2 (27 mg, 0.038 mmol). The mixture was degassed and purged with nitrogen three times, then stirred under a nitrogen atmosphere at 80°C for 20 hours. After cooling to room temperature, EA and water were added. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE / EA=32:3) to give compound 2-4 (100 mg, 59.0%) as a light brown solid. m / z(ESI) + :475.8[M+H] + .

[0192] Step 5: Synthesis of 4-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)oxy)-3-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine (397):

[0193] Similarly to step 7 of Example 1, 4-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)oxy)-3-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridine (397) was synthesized from compound 2-4 to give a white solid. 1 HNMR (400MHz, CD3OD) δ8.31(s,1H),8.14(s,1H),7.86(d,J=6.1Hz,1H),7.07(d,J=6.1Hz,1H),5.54-5.45(m,1H),4.67-4. 59(m,1H),3.76-3.68(m,2H),2.39-2.34(m,2H),1.60(d,J=6.7Hz,6H),1.47-1.38(m,2H),1.28(d,J=6.2Hz,6H).m / z(ESI) + :355.8[M+H] + .

[0194] Referring to Example 2, the compounds shown in Table 2 were prepared using appropriate corresponding starting materials.

[0195] Table 2 a SFC (chiral chromatography column Chiralpak-IC, 4.6 mm x 250 mm, 5 μm, eluent CO2-IPA (0.2% DEA)).

[0196] Example 3: Preparation of Compounds 407 and 421

[0197] Step 1: Synthesis of (2R,6S)-2,6-dimethyltetrahydro-4H-pyran-4-one (3-1)

[0198] To a solution of 2,6-dimethyl-4H-pyran-4-one (100 g, 0.810 mol) in ethanol (800 mL) was added Pd / C (10%, 10 g), and the mixture was stirred at 30°C under H2 (2 atm) for 8 h. The mixture was filtered through celite, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (PE / EA = 3:1) to give a crude product of compound 3-1 (53.0 g, 51.1%) as a colorless oil. m / z (ESI) +: 129.1 [m+H] + .

[0199] Step 2: Synthesis of (2R,6S)-2,6-dimethyltetrahydro-4H-pyran-4-one oxime (3-2)

[0200] A suspension of compound 3-1 (15 g, 0.12 mol), hydroxylamine hydrochloride (8.1 g, 0.12 mol) and NaOAc (19.7 g, 0.24 mol) in ethanol (150 mL) was heated to 60 ° C and stirred for 3 h. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated in vacuo to obtain a residue. The residue was diluted in EtOAc and washed with brine. The separated organic layer was dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA=3:7) to obtain compound 3-2 as a white solid (16.0 g, 95.6%). m / z(ESI)+:144.2[m+H] + .

[0201] Step 3: Synthesis of (2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-amine (3-3)

[0202] To a suspension of LiAlH4 (5.7 g, 0.15 mol) in THF (200 mL), a solution of compound 3-2 (7.2 g, 0.050 mol) was added dropwise at 0 ° C. The mixture was then heated to 60 ° C and stirred for 6 hours. After cooling to 0 ° C with an ice-water bath, water (5.7 mL), 15% NaOH aqueous solution (5.7 mL) and water (17.1 mL) were added sequentially to quench the reaction. Mg2SO4 was then added and stirred at room temperature for 1 hour. The mixture was filtered and the filtrate was concentrated under reduced pressure to give compound 3-3 (6.10 g, 94.5%) as a colorless oil. m / z(ESI)+:130.1[m+H] +.

[0203] Step 4: Synthesis of 4-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)oxy)-3-(1-isopropyl-1H-pyrazol-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridine (3-4)

[0204] A mixture of compound 1-4 (18.6 g, 46.5 mmol) and compound 3-3 (6.00 g, 46.5 mmol) in DIEA (100 mL) was stirred at 140 ° C for 36 h. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=97:3) to obtain compound 3-4 as a brown solid (10.0 g, 43.7%). m / z (ESI) +: 492.8 [m+H] + .

[0205] Step 5: Synthesis of 3-(6-((2S,6R)-2,6-dimethylmorpholinyl)pyrimidin-4-yl)-N-((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (3-5)

[0206] Under nitrogen protection, Pd (PPh 3 ) 2Cl 2 (280 mg, 0.400 mmol) and CuI (76 mg, 0.400 mmol) were added to a mixture of intermediate 3-4 (1.00 g, 2.00 mmol) and intermediate 1-2 crude product (purity about 60%, 1.4 g, 2.35 mmol) in DMF (20 mL). The mixture was degassed and purged with nitrogen 3 times, then stirred at 120 ° C for 2 hours. After cooling to room temperature and diluting with EtOAc and water, the separated organic layer was washed with brine, dried over anhydrous Na 2 SO 4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA = 1: 9) to obtain intermediate 3-5 (300 mg, 26.9%) as a light brown solid. m / z (ESI) +: 557.7 [m + H] + .

[0207] Step 6: Synthesis of 3-(6-((2S,6R)-2,6-dimethylmorpholinyl)pyrimidin-4-yl)-N-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (407) and 3-(6-((2S,6R)-2,6-dimethylmorpholinyl)pyrimidin-4-yl)-N-((2R,4S,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (421)

[0208] To a TFA (20 mL) solution of intermediate 3-5 (300 mg, 0.54 mol) was added TfOH (2 mL). The mixture was stirred at room temperature for 1 hour. Concentrated and diluted in EtOAc, washed with a 1 mol / L NaOH aqueous solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA=1:9) and then separated by preparative HPLC (water, Gemini 5 μm, C18 150x 21.2 mm, 20 mL / min, ACN / H2O (0.1% TFA)=33%: 67%, kept for 10 min) to obtain compound 407 (16.5 mg) RT=6.55 min and compound 421 (8.3 mg) RT=8.07 min as a white solid.

[0209] Compound 407: 1 HNMR (400MHz, CD3OD) δ8.65(s,1H),7.68(s,1H),7.56(d,J=7.2Hz,1H),7.03(d,J=7.2Hz,1H),4.50-4.30(m,2H),4.08-3. 96(m,1H),3.74-3.64(m,4H),2.70(t,J=11.8Hz,2H),2.23-2.16(m,2H),1.46-1.35(m,2H),1.31-1.24(m,12H); m / z(ESI) + :437.9[M+H] + .

[0210] Compound 421: 1 HNMR(400MHz,CD3OD)δ8.55(s,1H),7.74(s,1H),7.59(d,J=7.2Hz,1H),7.07(d,J=7.2Hz,1H),4.63-4.36(m,2H),4.32(s,1H),4 .01-3.93(m,2H),3.73-3.64(m,2H),2.70(t,J=11.8Hz,2H),2.03-1.94(m,2H),1.76-1.66(m,2H),1.30-1.24(m,12H); m / z(ESI) + :437.9[M+H] + .

[0211] Referring to Examples 1 and 3, the compounds listed in Table 3 were synthesized by substituting a suitable amine for (2R,6S)-2,6-dimethylmorpholine in Step 1 of Example 1 and / or substituting a suitable amine for 3-3 in Step 4 of Example 3. Compounds 527, 528, 561, and 562, for which no retention time (RT) is indicated, were prepared using chiral starting materials.

[0212] Table 3 a SFC (chiralpak-IC column, 4.6 mm x 250 mm, 5 μm, eluent: CO₂-EtOH (0.2% NH₄OH)). b Prep-HPLC (Waters, Gemini 5 μm, C18 150 x 21.2 mm, 20 mL / min, ACN / H2O (0.1% TFA) = 2%:98%, hold for 6 min, then 23%:77%, hold for 10 min).

[0213] Example 4: Preparation of Compound 422 and Compound 445

[0214] Step 1: Synthesis of 4-iodo-1-isopropyl-1H-imidazole (4-1)

[0215] To a solution of 4-iodo-1H-imidazole (20 g, 0.1 mol) and 2-iodopropane (21 g, 0.12 mol) in CH3CN (50 mL) was added Cs2CO3 (50 g, 0.15 mol). The resulting mixture was stirred at 60 ° C overnight. It was cooled to room temperature and filtered, and the filtrate was concentrated. The residue was dissolved in EtOAc, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography (PE / EA=1:1) to give compound 4-1 (20 g, 82%) as a colorless oil. m / z(ESI)+:236.8[m+H] + .

[0216] Step 2: Synthesis of (1-isopropyl-1H-imidazol-4-yl)boronic acid (4-2)

[0217] Under nitrogen protection, a solution of n-butyllithium (n-BuLi) in n-hexane (2.4M, 16mL, 38mmol) was slowly added dropwise at -75°C to a solution of compound 4-1 (3g, 13mmol) and 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde (7.1g, 38mmol). The mixture was stirred at -75°C for 2 hours. NH4Cl (saturated aqueous solution, 50mL) was added to the mixture to quench the reaction. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=10:1) to obtain compound 4-2 as a white solid (1.7g, 87%). m / z(ESI)+:155.2[m+H] + .

[0218] Step 3: Synthesis of N-((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-imidazol-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (4-3)

[0219] N-((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-imidazol-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (4-3) was synthesized from compounds 4-2 and 3-4 using a method similar to that in step 4 of Example 2 as a white solid. m / z (ESI)+: 475.2 [m+H] + .

[0220] Step 4: Synthesis of N-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-imidazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (422) and N-((2R,4S,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-imidazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (445)

[0221] To a solution of intermediate 4-3 (200 mg, 0.42 mol) in TFA (10 mL) was added TfOH (0.5 mL). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated and diluted in EtOAc, washed with a 1 M aqueous NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA=1:9) and then separated by SFC (chiralpak IC column, 4.6 mm x 250 mm, 5 μm, eluted with CO2-EtOH (0.2% NH4OH)) to obtain compound 422 (9 mg) RT=15.6 min and compound 445 (3 mg) RT=10.09 min as white solids.

[0222] Compound 422: 1 HNMR (400MHz, CD3OD) δ7.95(s,1H),7.79(s,1H),7.59(d,J=6.6Hz,1H),6.76(d,J=6.6Hz,1H),4.60-4.52(m,1H),4.17-4. 07(m,1H),3.75-3.65(m,2H),2.23-2.13(m,2H),1.58(d,J=6.6Hz,6H),1.38-1.31(m,2H),1.27(d,J=6.1Hz,1H); m / z(ESI) + :355.2[M+H] + .

[0223] Compound 445: 1 HNMR (400MHz, CD3OD)7.88(s,1H),7.84(s,1H),7.61(d,J=6.6Hz,1H),6.78(d,J=6.6Hz,1H),4.65-4.55(m,1H),4.45-4.3 7(m,1H),4.15-4.05(m,2H),1.98-1.88(m,2H),1.73-1.63(m,2H),1.59(d,J=6.6Hz,6H),1.25(d,J=6.1Hz,1H); m / z(ESI) + :355.2[M+H] + .

[0224] With reference to Examples 3 and 4, the compounds shown in Table 4 can be prepared by using a suitable amine instead of amine 3-3 in Step 4 of Example 3.

[0225] Table 4

[0226] Example 5: Preparation of Compounds 423 and 439

[0227] Step 1: Synthesis of 1-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde-2-yl)-1H-pyrazole (5-1)

[0228] To a suspension of NaH (60%, 0.24 g, 6 mmol) in DMF (10 mL) was added 3- (4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl) -1H pyrazole (1.04 g, 5.36 mmol) under a nitrogen atmosphere at 0 ° C. The mixture was stirred at 30 ° C for 30 minutes. It was then cooled to 0 ° C, and 2-iodopropane (0.8 mL, 8 mmol) was added dropwise. The resulting mixture was stirred at room temperature for another 30 minutes. A saturated aqueous solution of NH4Cl was added to the mixture to quench the reaction, which was then extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give a residue. The residue was purified by silica gel column chromatography (PE / EA = 4: 1) to give compound 5-1 (550 mg, 43%) as a colorless oil. 1 HNMR (300MHz, CD3OD) δ7.67(d,J=2.3Hz,1H),6.59(d,J=2.3Hz,1H),4.66-4.52(m,1H),1.48(d,J=6.7Hz,6H),1.19(s,12H).

[0229] Step 2: Synthesis of N-((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-pyrazol-3-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (5-2):

[0230] N-((2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-imidazol-4-yl)-1-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (5-2) was synthesized from compounds 5-1 and 3-4 in a manner similar to step 4 of Example 2 as a white solid. m / z (ESI) + :475.2[M+H] + .

[0231] Step 3: Synthesis of N-((2R,4R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (423) and N-((2R,4S,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-3-(1-isopropyl-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (439)

[0232] To a solution of intermediate 5-2 (200 mg, 0.42 mmol) in TFA (10 mL) was added TfOH (0.5 mL). The mixture was stirred at room temperature for 1 hour. The mixture was concentrated and diluted in EtOAc, washed with a 1M aqueous NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=10:1) and then separated by SFC (chiral chromatography column chiralpak IC column, 4.6 mm x 250 mm, 5 μm, eluted with CO2-IPA (0.2% NH4OH)) to obtain compound 423 (50 mg), RT=10.55 min, and compound 439 (17 mg), RT=7.90 min, as a white solid.

[0233] Compound 423: 1 HNMR (400MHz, CD3OD) δ7.86(d,J=2.4Hz,1H),7.61(d,J=6.9Hz,1H),6.95-6.90(m,2H),4.76-4.66(m,1H),4.21-4.13( m,1H),3.77-3.68(m,2H),2.28-2.21(m,2H),1.64(d,J=6.7Hz,6H),1.44-1.33(m,2H),1.29(d,J=6.2Hz,6H); m / z(ESI) + :354.9[M+H] + .

[0234] Compound 439: 1HNMR (400MHz, CD3OD) δ7.87(d,J=2.5Hz,1H),7.70(d,J=6.4Hz,1H),6.96(d,J=2.5Hz,1H),6.76(d,J=6.4Hz,1H),4.67-4.57(m,1H) ,4.54-4.49(m,1H),4.06-3.97(m,2H),2.04-1.97(m,2H),1.67-1.62(m,2H),1.60(d,J=6.8Hz,6H),1.23(d,J=6.2Hz,6H); m / z(ESI) + :354.9[M+H] + .

[0235] With reference to Examples 3 and 5, the compounds shown in Table 5 can be prepared by using a suitable amine instead of amine 3-3 in Step 4 of Example 3.

[0236] Table 5

[0237] Example 6: Preparation of Compound 523

[0238] Step 1: Synthesis of tert-butyl 2-(6-chloropyrimidin-4-yl)-2-cyanoacetate (6-1)

[0239] To a solution of 4,6-dichloropyrimidine (10 g, 0.067 mol) and tert-butyl 2-cyanoacetate (23.7 g, 0.168 mol) in THF (100 mL) was added sodium hydride (60%, 6.71 g, 0.168 mol) at 0°C under nitrogen. The reaction mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of NH4Cl was added to the mixture to quench the reaction, and then the pH was adjusted to 2-3 with a 1M aqueous solution of HCl. The mixture was extracted twice with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to give compound 6-1 (16 g, 94%) as a white solid. m / z (ESI) +: 253.9 [m+H] + .

[0240] Step 2: Synthesis of 2-(6-chloropyrimidin-4-yl)acetonitrile (6-2)

[0241] To a solution of intermediate 6-1 (11 g, 0.043 mol) in toluene (100 mL) was added p-toluenesulfonic acid monohydrate (0.82 g, 0.0043 mol). The mixture was stirred at 100° C. for 3 hours. The mixture was cooled to room temperature and diluted with EtOAc. The mixture was washed with a saturated aqueous solution of NaHCO 3 and brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA=7:3) to obtain compound 6-2 (5.5 g, 84%) as a yellow solid. m / z (ESI)+: 154.0 [m+H] + .

[0242] Step 3: Synthesis of 1-(6-chloropyrimidin-4-yl)cyclobutane-1-carbonitrile (6-3)

[0243] In an ice-water bath, a solution of intermediate 6-2 (612 mg, 4 mmol) and 1,3-dibromopropane (965 mg, 4.8 mmol) in DMF (10 mL) was added dropwise to a suspension of potassium carbonate (1.38 g, 10 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was diluted with EtOAc, then washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (PE / EA=1:1) to obtain compound 6-3 (600 mg, 78%) as a yellow solid. m / z(ESI)+:194.0[m+H] + .

[0244] Step 4: Synthesis of 1-(6-(trimethyltinyl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (6-4)

[0245] 1-(6-(trimethyltinyl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (6-4) was synthesized from compound 6-3 in a manner similar to step 2 of Example 1 as a yellow solid. m / z (ESI)+: 323.9 [m+H] + .

[0246] Step 5: Synthesis of 3-iodo-1-(4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (6-5)

[0247] A suspension of intermediate 1-4 (30 g, 0.075 mol), 2,2,2-trifluoroethylamine hydrochloride (30.5 g, 0.225 mol) and DBU (23 g, 0.15 mmol) in xylene (250 mL) was sealed and heated to 190° C. in an oil bath and stirred for 3 h. The mixture was cooled to room temperature and diluted in EtOAc, washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to obtain a residue. The residue was stirred in MTBE at room temperature for 30 minutes and filtered to obtain compound 6-5 (24 g, 69%) as a white solid. m / z (ESI)+: 463.1 [m+H] + .

[0248] Step 6: Synthesis of 1-(6-(1-(4-methoxybenzyl)-4-(2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (6-6)

[0249] 1-(6-(1-(4-methoxybenzyl)-4-(2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (6-6) was synthesized from compounds 6-4 and 6-5 in a manner similar to that in Step 5 of Example 3 as a yellow solid. m / z (ESI)+: 493.9 [m+H]+.

[0250] Step 7: Synthesis of 1-(6-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (523)

[0251] 1-(6-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (523) was synthesized from compound 6-6 as a yellow solid in a manner similar to that of step 6 of example 3. 1 HNMR (400MHz, DMSO-d6) δ13.65(s,1H),10.26(s,1H),8.08(s,1H),7.80(d,J=6.0Hz,1H),7.32(s,1H),6. 80(d,J=6.0Hz,1H),4.48-4.35(m,2H),3.92-3.81(m,2H),2.34-2.27(m,2H),1.90-1.80(m,2H); m / z(ESI) + :373.8[M+H] + .

[0252] Referring to Example 6, the compounds shown in Table 6 were prepared by using a suitable halogenated hydrocarbon instead of 1,3-dibromopropane in step 2, or using a suitable amine instead of 2,2,2-trifluoroethylamine in step 5.

[0253] Table 6

[0254] Example 7: Preparation of Compounds 521 and 509

[0255] Step 1: Synthesis of 2-(4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde-2-yl)-1H-pyrazol-1-yl)acetonitrile (7-1)

[0256] To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-1H pyrazole (10 g, 0.052 mol) in DMF (150 mL) was added sodium hydride (60%, 4.12 g, 0.103 mol) with stirring at 0°C. After stirring for 30 minutes, 2-bromoacetonitrile (12.35 g, 0.103 mol) was added. The mixture was stirred at room temperature overnight. A saturated aqueous solution of NH4Cl was added to the mixture to quench the reaction and extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=97:3) to obtain compound 7-1 (2.0 g, 17%) as an off-white solid. m / z(ESI)+:234.0[m+H] + .

[0257] Step 2: Synthesis of 5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzaldehyde-2-yl)-1H-pyrazol-1-yl)spiro[2.3]hexane-5-carbonitrile (7-2)

[0258] Under nitrogen protection, to a solution of LiHMDS (1M, 43mL, 43mmol) in THF (150mL) at -5°C to 0°C, a solution of intermediate 7-1 (2.05g, 8.8mmol) and 1,1-bis(bromomethyl)cyclopropane (2.0g, 8.8mmol) in THF (50mL) was added dropwise. The mixture was stirred at this temperature for 10 minutes, and then the reaction was quenched with formic acid. The mixture was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=99:1) to obtain compound 7-2 (170mg, 26%) as a colorless oil. m / z(ESI)+:300.0[m+H] + .

[0259] Step 3: Synthesis of 5-(4-(1-(4-methoxybenzyl)-4-(2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1H-pyrazol-1-yl)spiro[2.3]hexane-5-carbonitrile (7-3)

[0260] 5-(4-(1-(4-methoxybenzyl)-4-(2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1H-pyrazol-1-yl)spiro[2.3]hexane-5-carbonitrile (7-3) was synthesized as a yellow solid from compounds 7-2 and 6-5 in a manner similar to step 4 of Example 2. 1 HNMR (300MHz, CDCl3) δ8.04(s,1H),7.96(s,1H),7.87(d,J=6.1Hz,1H),7.20-7.15(m,2H),6.86-6.79(m,2H),6.68(d,J=6.1Hz,1H),5.43(s,2H ),5.16(t,J=6.3Hz,1H),4.37-4.24(m,2H),3.76(s,3H),3.34-3.26(m, 2H),3.03-2.95(m,2H),0.85-0.77(m,2H),0.67-0.59(m,2H); m / z(ESI) + :507.7[M+H] + .

[0261] Step 4: Synthesis of 3-ethylidene-1-(4-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile (521) and 5-(4-((2,2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1H-pyrazol-1-yl)spiro[2.3]hexane-5-carbonitrile (509)

[0262] 1-(6-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)cyclobutane-1-carbonitrile (521) and 5-(4-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)-1H-pyrazol-1-yl)spiro[2.3]hexane-5-carbonitrile (509) were synthesized from compound 7-3 as white solids in a manner similar to step 7 of Example 1.

[0263] Compound 521: RT = 8.3 min (preparative HPLC (GILSON, Gemini 5 μm, C18 150 x 21.2 mm, 20 mL / min, ACN / H2O (0.05% NH4OH) = 35%: 65% to 60%: 40%, within 10 min)); 1 HNMR(400MHz,CD3OD)δ8.26(s,1H),7.99(s,1H),7.84(d,J=6.2Hz,1H),6.89(d,J=6.2Hz,1H ),5.60-5.52(m,1H),4.28(q,J=9.5Hz,2H),3.79-3.64(m,4H),1.66-1.60(m,3H); m / z(ESI) + :387.8[M+H] + .

[0264] Compound 509: RT = 7.7 min (preparative HPLC (GILSON, Gemini 5 μm, C18 150 x 21.2 mm, 20 mL / min, ACN / H2O (0.05% NH4OH) = 35%: 65% to 60%: 40%, within 10 min)); 1 HNMR(400MHz,CD3OD)δ8.30(s,1H),7.99(s,1H),7.84(d,J=6.2Hz,1H),6.89(d,J=6.2Hz,1H),5.60-5.52 (m,1H),4.29(q,J=9.5Hz,2H),3.30-3.26(m,2H),3.04-2.98(m,2H),0.83-0.77(m,2H),0.66-0.59(m,2H); m / z(ESI) + :387.9[M+H] + .

[0265] Example 8: Preparation of Compound 526

[0266] Step 1: Synthesis of 3-(6-((1R,5S)-6-oxa-3-azabicyclo[3.1.1]heptane-3-yl)pyrimidin-4-yl)-1-(4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (8-1)

[0267] 3-(6-((1R,5S)-6-oxa-3-azabicyclo[3.1.1]heptane-3-yl)pyrimidin-4-yl)-1-(4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (8-1) was synthesized from 4,6-dichloropyrimidine using appropriate reagents at appropriate steps.

[0268] Step 2: Synthesis of (3S,5R)-1-(6-(4-((2,2,2-trifluoroethyl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrimidin-4-yl)piperidine-3,5-diol (526)

[0269] To a solution of compound 8-1 (90 mg, 0.176 mmol) in TFA (10 mL) was added TfOH (0.5 mL). The resulting mixture was stirred at room temperature for 1 h, then concentrated, diluted with DCM, and then washed with a 1 M NaOH aqueous solution and brine. The separated organic layer was dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by preparative TLC (DCM / MeOH=5:1) and by preparative HPLC (Gilson, Gemini 5μm, C18150x21.2mm, 20mL / min, ACN / H2O (0.1% FA)=35%:65%~50%:50%in 10min) to obtain compound 526 (20 mg) as a white solid. 1 HNMR (400MHz, CD3OD) δ8.58(d,J=1.0Hz,1H),7.77(d,J=6.3Hz,1H),7.71(d,J=1.0Hz,1H),6.87(d,J=6.3Hz,1H) ,4.39(q,J=9.5Hz,2H),4.16-4.08(m,2H),4.05-3.90(m,2H),3.68-3.58(m,2H),1.95(t,J=5.4Hz,2H).m / z(ESI) + :410.0[M+H] + .

[0270] Example 9: Preparation of Compound 522

[0271] Step 1: Synthesis of (2R,6S)-4-(2-bromopyridin-4-yl)-2,6-dimethylmorpholine (9-1)

[0272] Under a nitrogen atmosphere, cuprous iodide (70 mg, 0.352 mmol) and L-proline (80 mg, 0.704 mmol) were added to a suspension of 2-bromo-4-iodopyridine (1.0 g, 3.52 mmol), (2R, 6S)-2,6-dimethylmorpholine (400 mg, 3.52 mmol) and K2CO3 (1.5 g, 10.5 mmol) in DMSO (20 mL) under a nitrogen atmosphere. The resulting mixture was degassed and purged with nitrogen three times, then stirred at 60 ° C for 1 h. The reaction mixture was diluted with EtOAc and washed with brine. The separated organic layer was dried over anhydrous Na2SO4, filtered and concentrated to obtain a residue. The residue was purified by silica gel column chromatography (DCM / MeOH=99:1) to obtain compound 9-1 (400 mg, 42%) as a white solid. m / z (ESI) +: 270.8, 272.8 [m+H] + .

[0273] Step 2: Synthesis of 3-(4-((2S,6R)-2,6-dimethylmorpholinyl)pyridin-2-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (522)

[0274] 3-(4-((2S,6R)-2,6-dimethylmorpholinyl)pyridin-2-yl)-N-(2,2,2-trifluoroethyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (522) was synthesized from compound 9-1 in a manner similar to that of Example 1 using appropriate reagents at appropriate steps. 1 HNMR (400MHz, CDCl3) δ8.25(d,J=6.1Hz,1H),7.87(d,J=6.1Hz,1H),7.76(d,J=2.6Hz,1H),6.71(dd,J=6 .1,2.6Hz,2H),4.50-4.36(m,2H),3.81-3.71(m,4H),2.66-2.58(m,2H),1.30(d,J=6.2Hz,6H.m / z(ESI) + :406.8[M+H] + .

[0275] Preparation Example: Synthesis of Reference Compound

[0276] The above-mentioned reference compound was synthesized by referring to the method of Example 1, except that: step 1 was not performed, 2-chloropyridine was used for step 2, the prepared 2-(trimethyltin)pyridine was replaced by compound 1-2 in Example 1, and CF3CH2NH2 was used to replace cyclopropaneamine in step 5 to obtain the reference compound.

[0277] Example 10 Kinase inhibition assay

[0278] Material

[0279] Kinase LRRK2 G2019S protein was from Carna, LRRKtide was from Signalchem, ATP was from Promega, and DMSO was from Sigma.

[0280] Kinase assay method

[0281] All assays were performed at room temperature. Test compounds were diluted and added to a 384-well plate. 2.5 μL of 2× kinase reaction buffer was added and the plate was centrifuged. 2.5 μL of 2× substrate and ATP mix was added and centrifuged. 4 μL of ADP-Glo ​​reagent was added and the plate was incubated at room temperature for 40 minutes. 8 μL of LRRKtide was added and the plate was incubated at room temperature for 40 minutes. The data were then read using an Envision 2104 multi-label reader.

[0282] result

[0283] IC of the compounds of the present disclosure for inhibition of LRRK2 G2019S 50 The values ​​are shown in Table 3 below.

[0284] Table 3

[0285] Example 11 HEK293 cell kinase inhibition assay

[0286] HEK293 cells were cultured, trypsin was added to collect the cells, and culture medium was added to adjust the cell density to 2 × 10 5 / ml. Liposome-DNA complexes were constructed and mixed with HEK293 cells at a ratio of 1:20, added to 384-well plates, and incubated at 37°C for 20-30 hours. A mixed solution of enzyme substrate and test compound was added, incubated at room temperature for 2-3 minutes, and NanoBRET reagent (Promega) was added. Within 10 minutes, the bioluminescence of the donor luciferase protein (donor) at 450 nm and the acceptor fluorescent group (acceptor) at 610 nm were read using a microplate reader (Envision 2104). The BRET ratio of the test article was calculated according to the following formula, including the background correction option.

[0287] Acceptor sample : 610 nm fluorescence of the compound to be tested;

[0288] Donor sample : 450nm fluorescence of the compound to be tested;

[0289] Acceptorno-tracercontrol: background (no test compound added) fluorescence at 610 nm;

[0290] Donorno-tracer control: background (no test compound added) 450nm fluorescence

[0291] The inhibitory activity of the test compound on the cell LRRK2 enzyme was calculated by the following formula:

[0292] Percent inhibition rate = 100 - (BRET ratio of test product - average BRET ratio of positive control in the whole microplate) / (average BRET ratio of negative control in the whole microplate - average BRET ratio of positive control in the whole microplate) × 100.

[0293] IC of the test compound on the cellular LRRK2 enzyme 50 Calculation: Graphpad software was used to perform nonlinear regression fitting of the percentage inhibition rate and compound logarithmic concentration curves (dose-effect-variable slope method).

[0294] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*Hill Slope))

[0295] X: Logarithmic inhibitor concentration; Y: Percent inhibition rate; Bottom: Minimum value; Top: Maximum value; Hill Slope: Hill slope

[0296] result

[0297] IC of some examples of compounds in the present disclosure on LRRK2, LRRK2-2019S and LRRK2-R1441C inhibition in HEK293 cells 50 The values ​​are summarized in the following table:

[0298] Example 12 In vivo efficacy study of oral administration in mice

[0299] 1. Experimental purpose: To determine the in vivo efficacy of compound 527 by observing the inhibitory effect of oral administration of compound 527 on the phosphorylation level of LRRK2 in the brain of mice with the G2019S mutant LRRK2 gene.

[0300] 2. Experimental methods:

[0301] (1) Animals: B6.Cg-Tg(Lrrk2*G2019S)2Yue / J transgenic mice were purchased from Jackson Laboratory and mated with C57BL / 6J mice to obtain LRRK2 heterozygous mice carrying the G2019S mutation (LRRK2-G2019S mice). Half male and half female, weighing 16-20 g and aged 15-17 weeks.

[0302] (2) Grouping and Dosing: Mice were randomly divided into five experimental groups based on body weight, with eight animals in each group, four males and four females. The specific dosing for the experimental groups is shown in Table 1 below. Group G1 was the vehicle control group, and groups G2 to G5 were administered with 527 compound at doses of 1 mg / kg, 3 mg / kg, 10 mg / kg, and 30 mg / kg, respectively:

[0303] Table 1: Experimental groups and drug administration methods

[0304] (3) Determination of LRRK2 activity in the brain: One hour after administration, the animals were euthanized with CO2, and the brain tissue was collected and quickly frozen with liquid nitrogen and then stored at -80°C until subsequent experiments. TM Cells were homogenized in RIPA buffer with a protease inhibitor cocktail (Roche, 04693124001) and a phosphatase inhibitor cocktail 2 (Sigma, R0278), and protein quantification was performed using the BCA assay. Western blot analysis was performed to determine the levels of phosphorylated LRRK2 at position S935 (anti-LRRK2 (phospho S935) antibody, abcam, ab133450) and total LRRK2 (anti-LRRK2 antibody, abcam, ab133518). Brain LRRK2 activity was expressed as the ratio of phosphorylation of LRRK2 at position S935 to total LRRK2 (pS935-LRRK2 / LRRK2).

[0305] (4) Results and conclusions: The typical results of brain tissue Western Blot are shown in Figure 1, and the inhibitory effect of compound 527 on LRRK2 phosphorylation in brain tissue is shown in Figure 2.

[0306] The results showed that the onset dose of compound 527 for inhibiting LRRK2 phosphorylation in brain tissue after oral administration was 10 mg / kg, and the maximum effective dose (defined as 60% inhibition of LRRK2 phosphorylation level) was 30 mg / kg. The corresponding human equivalent doses (calculated based on a body weight of 70 kg) were 57 mg and 171 mg, respectively.

[0307] The above describes exemplary embodiments of the present disclosure. However, the scope of protection of the present disclosure is not limited to the above embodiments. Any modifications, equivalent substitutions, or improvements made by those skilled in the art within the spirit and principles of the present disclosure shall be included in the scope of protection of the present disclosure.

Claims

1. A compound represented by formula (I), its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound: in: W is selected from N or O; R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group; Every R a The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy; Alternatively, two R a Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R c Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy; R 2 Not present or selected from H or C 1-10 Alkyl; wherein, when W is selected from O, R 2 Not present; when W is selected from N, R 2 Selected from H or C 1-10 alkyl; Alternatively, R 1 、R 2 Together with W, it forms an unsubstituted or optionally substituted group consisting of one, two or more R b substituted 3-10 membered heterocyclic group; Every R b The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy; Alternatively, two R b Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R c Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy; Every R c The same or different, independently selected from halogen, hydroxyl, C 1-10 Alkyl, C 1-10 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 Cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy; X is selected from one, two or more R 3 substituted 5-10 membered heteroaryl; Every R 3 The same or different, independently selected from unsubstituted or substituted by one, two or more R 4 Substituted with the following groups: C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; Alternatively, two R 3 Together with the atoms to which it is attached, it forms an unsubstituted or optionally substituted group consisting of one, two or more R 4 Substituted with the following groups: C 3-10 Cycloalkyl, 3-10 membered heterocyclic group; Every R 4 The same or different, independently selected from halogen, hydroxyl, cyano, unsubstituted or replaced by one, two or more R d Substituted with the following groups: C 1-10 Alkyl, C 1-10 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, 5-10 membered heteroaryl; wherein, when R 4 Selected from C 1-6 When alkylene is 4 The carbon atom in R 3 The carbon atoms to which they are attached form a double bond; Every R d The same or different, independently selected from halogen, hydroxy, cyano, C 1-6 Alkyl, C 1-6 Alkyloxy, C 3-10 Cycloalkyl, C 3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy.

2. The compound according to claim 1, its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, characterized in that: Every R a The same or different, independently selected from F, Cl, Br, C 1-6 alkyl; R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-8 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group; for example, R 1 Selected from unsubstituted or substituted by one, two or more R a Substituted with the following groups: C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclic group; for example, R 1 Selected from -CH2CF3, -CH(CH3)CF3; Or, R 1 、R 2 Together with W, it forms an unsubstituted or optionally substituted group consisting of one, two or more R b Substituted with the following groups: X is selected from one, two or more R 3 substituted 5-6 membered heteroaryl; for example, X is selected from one, two or more R 3 Replaced For example, X is selected from Every R 4 The same or different, independently selected from fluorine, chlorine, bromine, hydroxyl, cyano, unsubstituted or replaced by one, two or more R d Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkylene, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group; R 3 Selected from unsubstituted or substituted by one, two or more R 4 Substituted with the following groups: C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, 5-6 membered heteroaryl; For example, R 3 Selected from unsubstituted or substituted by one, two or more R 4 Substituted groups: methyl, ethyl, propyl, isopropyl, cyclopropane, cyclobutane, For example, R 3 Selected from isopropyl, 3. The compound according to claim 1 or 2, its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, characterized in that: The compound represented by formula (I) has the structure represented by the following formula (II): Among them, R 5 Selected from C substituted by one, two or more halogens 1-6 Alkyl, preferably C substituted by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 halogens 1-6 Alkyl, for example methyl or ethyl substituted by 1, 2, 3, 4 or 5 fluorine or chlorine atoms, for example trifluoromethyl; R 6 Selected from C 1-6 an alkyl group, such as methyl, ethyl, propyl or isopropyl; R 7 、R 8 、R 9 、R 10 The same or different, independently selected from H or C 1-6 Alkyl, such as H, methyl, ethyl, propyl or isopropyl; R 11 、R 12 The same or different, independently selected from H or C 1-6 Alkyl, such as H, methyl, ethyl, propyl or isopropyl.

4. The compound according to claim 3, its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, wherein: The compound represented by formula (I) has the following compound represented by formula (III): Among them, R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 、R 12 It has the definition described in claim 3.

5. The compound according to claim 1, its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, wherein: The compound represented by formula (I) is selected from the following compounds:

6. A method for preparing the compound according to any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound, characterized in that: The preparation method comprises the following reactions: Among them, R 1 、R 2 , W and X have the definitions given above; P 1 is selected from amino protecting groups; Preferably, the compound of formula (M2) is 1 to obtain a compound represented by formula (I); Preferably, the P 1 selected from alkyloxycarbonyl (e.g., tert-butoxycarbonyl, etc.), cycloalkylalkoxycarbonyl (e.g., cyclohexylmethoxycarbonyl), substituted alkyloxycarbonyl (e.g., trichloroethoxycarbonyl, etc.), substituted arylalkyloxycarbonyl (e.g., p-nitrobenzyloxycarbonyl), arylalkyl (e.g., trityl or benzhydryl), heteroarylalkyl (e.g., pyridylalkyl, for example, 2-pyridylmethyl, 4-pyridylmethyl), alkoxyarylalkyl (e.g., alkoxyphenylalkyl, for example, p-methoxybenzyl); Preferably, the preparation method further comprises the following reaction: Among them, R 1 、R 2 , W, X, and P 1 has the meaning given above; L 1 and L 2 The same or different, independently selected from leaving groups capable of undergoing a coupling reaction; Preferably, the compound of formula (M2) can be prepared by coupling reactions known in the art, such as Stille coupling reaction or Suzuki coupling reaction; For example, L 1 Can be selected from halogen, such as iodine; L 2 It may be selected from an alkyltin group or a borate group.

7. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises at least one of the compound according to any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof; Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients; Preferably, the pharmaceutical composition is in unit dosage form, and each unit dosage form may contain about 1 to 1000 mg, for example about 5 to 1000 mg, more usually about 5 to 500 mg, such as 5 to 100 mg, 100 to 500 mg or 50 to 200 mg of the active ingredient; Preferably, the compound, its racemate, stereoisomer, tautomer, isotopically labeled, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound is administered at a dosage range of about 1 μg / kg to about 1 g / kg body weight / day, for example, 0.01 mg / kg to about 100 mg / kg body weight / day; When the subject of administration is a human, the dose administered to the patient may be 57 mg / 70 kg to 171 mg / 70 kg.

8. Use of at least one of the compound according to any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotope-labeled substance, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester or prodrug compound thereof in the preparation of a medicament, characterized in that: The medicament is used for diseases or disorders associated with LRRK kinase, especially LRRK2 kinase activity.

9. Use of at least one of the compound of any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotopically labeled, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug thereof in an analytical test for identifying compounds capable of inhibiting one or more kinases, preferably LRRK, more preferably LRRK2; Preferably, the analytical test is a competitive binding activity assay.

10. A method for detecting binding of a compound to a kinase, the method comprising the following steps: (i) contacting at least one of the compound according to any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotope-labeled form, N-oxide, hydrate, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or prodrug compound thereof with the kinase in the presence of the kinase and a known substrate; (ii) detecting any changes in the interaction between said kinase and said known substrate.